Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction.

Document Type

Article

Publication Date

11-1-2018

Institution/Department

Center for Molecular Medicine; Maine Medical Center Research Institute

Journal Title

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals

MeSH Headings

Epidermal Growth Factor, Female, Heart Failure, Humans, Male, Middle Aged, Neuregulin-1, Neuregulins, Predictive Value of Tests, Prognosis, Stroke Volume, Ventricular Dysfunction, Left

Abstract

CONTEXT: Improved left ventricular ejection fraction (LVEF) following administration of recombinant human Neuregulin-1β (NRG), epidermal growth factor (EGF) involved in cardiomyocyte repair/survival, has been observed in patients with systolic heart failure (HF).

METHODS: Serum NRG was measured by ELISA in 248 patients with NYHA class I-IV HF.

RESULTS: NRG exhibited a marginally significant effect on LVEF trajectory over 11 months (p = 0.07). There is no apparent level of NRG that predicts improved survival.

CONCLUSIONS: There is a potential relationship between serum NRG and improved LVEF, indicating the need to investigate the utility of NRG in predicting HF outcomes, including LVEF maintenance.

ISSN

1366-5804

First Page

704

Last Page

708

Share

COinS